LiVeritas Biosciences, Inc. has recently unveiled an innovative laboratory ecosystem called the LiLii™ platform, which is powered by artificial intelligence (AI). This groundbreaking platform brings together lab best practices, analytical operations, project management, and communications to support drug developers in their work.
The LiLii™ platform represents the next generation of fully integrated laboratory ecosystems. It leverages the proprietary LiVeritas® AI technology to simplify workflows, reduce inefficiencies, and enhance productivity for drug developers at every stage of development. As a Software-as-a-Service (SaaS) platform, it combines powerful analytical tools with an extensive biopharma knowledge base driven by AI. This empowers drug developers with streamlined data processing, analysis, and reporting capabilities through a single intuitive interface.
By eliminating the need for multiple software packages, the LiLii™ platform promises to significantly accelerate the speed of drug development. It achieves this by generating high-quality data and analytics more efficiently than traditional manual methods. Additionally, it offers comprehensive project management features, customer relationship management (CRM) capabilities, document management solutions, and seamless communication tools all in